<DOC>
	<DOCNO>NCT00246922</DOCNO>
	<brief_summary>The aim long-term study investigate effect roflumilast ( APTA-2217 ) long-term safety patient asthma , complete 24-week evaluation study APTA-2217-05 . Roflumilast administer orally daily . The present study consist 28 week treatment period , extension 24-week study APTA-2217-05 ( register study ) . The study provide long-term safety efficacy data roflumilast .</brief_summary>
	<brief_title>Long-term Study Safety Efficacy Roflumilast Japanese Patients With Bronchial Asthma ( 20 71 ) ( APTA-2217-07 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Main inclusion criterion : Patients asthma disease Written inform consent Patients complete 24week evaluation study APTA221705 Main exclusion criterion : % FEV1.0 &lt; 60 % 18 week 24 week measurement APTA221705 Patients poorly control asthma informed consent day study start day : need oral intravenous steroid therapy , hospitalization emergency visit , PEF value worsen 2 consecutive day Serious disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Roflumilast</keyword>
	<keyword>phosphodiesterase 4 inhibitor</keyword>
</DOC>